Isolation and Characterization of Laminin-10/11 Secreted by Human Lung Carcinoma Cells : LAMININ-10/11 MEDIATES CELL ADHESION THROUGH INTEGRIN α3β1 by Kikkawa, Yamato et al.
Title
Isolation and Characterization of Laminin-10/11
Secreted by Human Lung Carcinoma Cells :
LAMININ-10/11 MEDIATES CELL ADHESION THROUGH
INTEGRIN α3β1
Author(s) Kikkawa, Yamato; Sanzen, Noriko; Sekiguchi,Kiyotoshi







Osaka University Knowledge Archive : OUKA
https://ir.library.osaka-u.ac.jp/repo/ouka/all/
Osaka University
Isolation and Characterization of Laminin-10/11 Secreted by
Human Lung Carcinoma Cells
LAMININ-10/11 MEDIATES CELL ADHESION THROUGH INTEGRIN a3b1*
(Received for publication, January 26, 1998, and in revised form, April 8, 1998)
Yamato Kikkawa, Noriko Sanzen, and Kiyotoshi Sekiguchi‡
From the Research Institute, Osaka Medical Center for Maternal and Child Health, 840 Murodo, Izumi,
Osaka 594-1101, Japan
A panel of human tumor cell lines was screened for
selective expression of laminin a5 chain, a newly iden-
tified laminin subunit comprising laminin-10 (a5b1g1)
and -11 (a5b2g1). The lung adenocarcinoma cell line
A549 was found to express the a5 chain at relatively high
levels but no detectable amounts of other a chains. The
laminin variants containing a5 chain were purified from
the conditioned medium of A549 cells by immunoaffinity
chromatography using the anti-laminin monoclonal an-
tibody 4C7 which was shown recently to recognize the
laminin a5 chain (Tiger, C.-F., Champliaud, M.-F.,
Pedrosa-Domellof, F., Thornell, L.-E., Ekblom, P., and
Gullberg, D. (1997) J. Biol. Chem. 272, 28590–28595). The
purified laminin variants consisted of three chains with
molecular masses of 350, 220, and 210 kDa. The 350-kDa
chain was specifically recognized by another anti-a5
chain monoclonal antibody capable of recognizing dena-
tured a5 chain on immunoblots, whereas the 210-kDa
chain was recognized by an anti-g1 chain antibody. The
purified a5 chain-containing laminin variants (hereaf-
ter referred to as laminin-10/11) were highly active in
mediating adhesion of A549 cells to the substratum with
potency as high as that of laminin-5 and significantly
higher than those of laminin-1, laminin-2/4, or fibronec-
tin. Adhesion to substrata coated with laminin-10/11 was
specifically inhibited by anti-integrin antibodies di-
rected against the integrin a3 or b1 subunit but not by
those against a2 or a6 subunit, indicating that laminin-
10/11 is specifically recognized by integrin a3b1. Given
the wide distribution of laminin-10/11 in the basement
membrane of various tissue types and dominant expres-
sion of integrin a3b1 in most epithelial cells, specific
interaction of laminin-10/11 with integrin a3b1 may play
an important role in in vivo regulation of proliferation
and differentiation of epithelial cells through the base-
ment membrane.
Laminins are a family of basement membrane proteins im-
plicated in diverse functions of epithelial and neuronal cells
including adhesion, migration, proliferation, differentiation,
and programmed cell death. Laminins are disulfide-linked het-
erotrimers of three distinct but distantly related subunit
chains termed a, b, and g. Nine genetically distinct laminin
chains, i.e. a1–5, b1–3, and g1–2, have been identified in man
and mouse (1). Combinations of these chains generate at least
11 different laminin variants, although the differences in bio-
logical functions among these variants are understood only
poorly.
Interaction of cells with laminins is mediated by a variety of
cell surface receptors including integrins, membrane-bound
proteoglycans (e.g. dystroglycan), and other membrane glyco-
proteins, of which integrins are of crucial importance with
respect to the control of growth and differentiation of cells by
the basement membrane (2). To date, nine different integrins
(a1b1, a2b1, a3b1, a6b1, a6b4, a7b1, a9b1, avb3, and a?b8)
have been suggested to be receptors for laminins (3). Specific-
ities of interactions of various laminin variants with integrins
have been investigated extensively with laminin-1 (a prototype
laminin purified from the EHS1 tumor), laminin-2/4 (merosin),
and laminin-5 (also referred to as kalinin, epiligrin, nicein, or
ladsin), but those of other newly identified laminins, particu-
larly those containing a4 and a5 chains, remain to be defined.
Laminin-10/11 is composed of a5, b1/2, and g1 chains (4).
The laminin a5 chain was cloned initially in mouse and found
to be more related to a Drosophila laminin a chain than to
other laminin a chains (5). cDNA clones encoding the G-domain
of the human a5 chain were isolated, and the gene encoding it
has been mapped to chromosome 20q13.2-13.3 (6). In contrast
to other laminin a chains, a5 is expressed widely in adult
tissues including placenta, heart, lung, skeletal muscle, kid-
ney, and pancreas (4–10), suggesting that laminin-10/11 may
be the major laminin isoforms in the adult basal laminae.
Despite its wide distribution in the body, however, the biolog-
ical functions and integrin binding specificity of laminin-10/11
are yet to be defined with purified proteins.
In the present study we screened a panel of human tumor
cell lines for those selectively expressing laminin-10/11. One of
the human lung adenocarcinoma cell lines, A549, was found to
express the a5 chain at high levels but no detectable amounts
of other a chains. Purification of laminin-10/11 from the con-
ditioned medium of A549 cells allowed us to characterize the
cell adhesive activity and integrin binding specificity of these
widely expressed laminin variants.
EXPERIMENTAL PROCEDURES
Materials—Laminin-1 was purified from mouse EHS tumor tissues
by the method of Paulsson et al. as described previously (11). Laminin-5
was purified from the conditioned medium of the human gastric carci-
noma line MKN45 by immunoaffinity chromatography using affinity-
purified rabbit polyclonal antibody against human laminin g2 chain
(12). Human laminin-2/4 (merosin) was purchased from Chemicon* This work was supported by special coordination funds from the
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article must therefore be hereby marked “advertisement” in accordance
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(Temecula, CA). Plasma fibronectin was purified from outdated human
plasma by gelatin-affinity chromatography (13).
Cell Lines and Culture Conditions—The human lung adenocarci-
noma cell line A549 and other human tumor cell lines used in this study
were obtained from Japanese Cancer Research Resources Bank (Tokyo,
Japan), except for the human lung squamous carcinoma cell RERF-
LC-AI and the cervix epidermoid carcinoma cell CaSki, which were
obtained from RIKEN Gene Bank (Tsukuba, Japan) and American
Type Culture Collection (Rockville, MD), respectively. These cells were
grown in DMEM supplemented with 15 mM HEPES (pH 7.2), 100
units/ml penicillin G, 0.1 mg/ml streptomycin sulfate, and 10% fetal
bovine serum (JRH Bioscience, Lenexa, KS) unless otherwise indicated,
at 37 °C in a humidified atmosphere of 5% CO2 and 95% air.
RT-PCR and Isolation of cDNAs Encoding Human Laminin a
Chains—Total RNA was extracted from cultured cells by the acid gua-
nidinium isothiocyanate method (14). cDNA was synthesized using a
First Strand Synthesis Kit (Amersham Pharmacia Biotech) according
to the manufacturer’s protocol. A cDNA fragment encoding domain IIIb
of the human laminin a5 chain was amplified by RT-PCR from CaSki
cells using the primers 59-TGTATCTGTCCACCACGCACTG-39 (sense
strand) and 59-ACATCTTGAGCCCTGCACGTTC-39 (antisense strand),
which were modeled after the cDNA sequence 4258–4587 of mouse
laminin a5 chain (5). The resulting 330-base PCR product was isolated
on a low melting point agarose gel and ligated into EcoRV-cleaved
pBluescript II KS(1). The nucleotide sequence of the amplified cDNA,
deposited into GenBank under accession number AB010099, was 86%
homologous to the corresponding sequence of mouse a5 chain cDNA. A
pair of nested primers, 59-GACTGCCTGCTGTGCCAGC-39 (sense
strand) and 59-GGGGTAGCCATGAAAGCCCG-39 (antisense strand),
was used for routine amplification of the laminin a5 chain transcript by
RT-PCR. The RNA transcripts encoding the domain IIIb of human
laminin a1 chain were also amplified by RT-PCR using primers 59-
AAGTGTGAAGAATGTGAGGATGGG-39 (sense strand; nucleotides
3020–3043 (7)) and 59-CACTGAGGACCAAAGACATTTTCCT-39 (anti-
sense strand; nucleotides 3312–3336). Similarly, the transcripts encod-
ing human laminin b1, b2, and g1 chains were amplified using the PCR
primers 59-AACTGTGAGCAGTGCAAGCCGTTT-39 (sense strand for
b1 chain; nucleotides 1054–1077 (15)), 59-CAACCAAATGGATCTTC-
ACTGCTT-39 (antisense strand for b1 chain; nucleotides 1278–1301),
59-CACTGTGAGCTCTGTCGGCCCTTC-39 (sense strand for b2 chain;
nucleotides 1153–1176 (16)), 59-CAAGGAGTGCTCCCAGGCACTG-
TG-39 (antisense strand for b2 chain; nucleotides 1427–1451), 59-CACT-
GTGAGAGGTGCCGAGAGAAC-39 (sense strand for g1 chain; nucleo-
tides 1033–1056 (17)), and 59-CATCCTGCTTCAGTGAGAGAATGG-39
(antisense strand for g1 chain; nucleotides 1203–1226). PCR products
were amplified under the following conditions: 30 cycles at 94 °C for 1
min, 61 °C (a5 and b2 chains), 57 °C (g1 chain), 55 °C (a1 chain) or
53 °C (b1 chain) for 1 min, and 72 °C for 1 min. PCR products were
analyzed by electrophoresis using 2% agarose gels.
Monoclonal Antibodies—Monoclonal antibodies against human lami-
nin a5 and a1 chains were produced by fusion of SP2/0 mouse myeloma
cells with splenocytes from mice immunized with GST fusion proteins
containing the IIIb domain of each laminin a chain. GST fusion proteins
were expressed in Escherichia coli using pGEX4T-1 (Amersham Phar-
macia Biotech) and purified on glutathione-Sepharose. Hybridomas
were first screened for reactivity with GST fusion proteins used as
immunogens and then selected for reactivity on immunoblots with
intact human laminin a chains secreted by human lung carcinoma cells.
Monoclonal antibodies against human laminin b1 chain (4E10) and g1
chain (2E8) were purchased from Chemicon. Monoclonal antibodies
against integrin a5 and b1 subunits, 8F1 and 4G2, were produced and
characterized in our laboratory and were described previously (18).
Monoclonal antibodies against laminin-2/4 were also produced by im-
munizing mice with human laminin-2/4 and screened for positive reac-
tivity with reduced, denatured a2 chain on immunoblots. One of these
antibodies, 10G1, specifically stained ;300-kDa a2 chain but not ;200-
kDa b/g chains. Monoclonal antibodies against human integrin a2 and
a3 subunits, P1E6 and P1B5, respectively, were purchased from Life
Technologies, Inc., and the monoclonal antibody against human inte-
grin a6 subunit (GoH3) was from Cosmo Bio (Tokyo).
Screening of Human Tumor Cells for Expression of Laminin Vari-
ants—31 human tumor-derived cell lines (13 lung carcinomas, 4 gastric
carcinomas, 3 cervix carcinomas, 3 gliomas, 2 kidney carcinomas, 2
choriocarcinomas, 1 fibrosarcoma, 1 hepatoma, 1 oral carcinoma, and 1
pancreatic carcinoma) were grown to confluence in 15-cm culture dishes
with DMEM containing 10% fetal bovine serum. The conditioned media
were harvested and clarified by sequential centrifugation at 1,500 3 g
for 10 min and 15,000 3 g for 30 min followed by precipitation with
ammonium sulfate at 40% saturation. The resulting precipitates were
collected by centrifugation at 15,000 3 g for 40 min and then dissolved
in and dialyzed against 10 mM Tris-HCl (pH 7.5) containing 150 mM
NaCl. The precipitates were screened for the expression of laminin a
chains by immunoblotting with antibodies specific to each a chain.
Purification of Laminin 10/11—The human lung adenocarcinoma
cell line A549 was grown to confluence in 1,700-cm2 roller bottles with
DMEM containing 10% fetal bovine serum (400 ml/bottle). After the
cells reached confluence, the conditioned medium was harvested once
every 6 days and clarified by centrifugation. Pooled conditioned me-
dium (3–5 liters) was first precipitated with 40% ammonium sulfate
and then dissolved in and dialyzed against phosphate-buffered saline
(8.1 mM Na2HPO4, 1.5 mM KH2PO4, 137 mM NaCl, and 2.7 mM KCl, pH
7.4). The precipitated proteins were subjected to immunoaffinity chro-
matography with the monoclonal anti-human laminin antibody 4C7
which was shown recently to recognize the laminin a5 chain (19). The
affinity column was prepared by coupling 1 mg of 4C7 IgG purified from
ascites (Life Technologies, Inc.) using protein G-Sepharose 4B (Amer-
sham Pharmacia Biotech) to CNBr-Sepharose 4B (Pharmacia). The
bound proteins were eluted from the 4C7 column with 0.1 M triethyl-
amine (pH 11.5), neutralized, and dialyzed against phosphate-buffered
saline.
Electrophoretic Analysis and Immunoblotting—SDS-PAGE was car-
ried out on 4% gels under nonreducing or reducing conditions (20). For
immunoblotting, proteins were separated by SDS-PAGE and trans-
ferred onto polyvinylidene difluoride membranes. Proteins on the mem-
brane were reacted with chain-specific monoclonal antibodies followed
by incubation with goat anti-mouse IgG antibody conjugated with
horseradish peroxidase (EY Laboratories, San Mateo, CA). Bound an-
tibodies were visualized with ECL Western blotting detection regents
(Amersham Pharmacia Biotech).
Cell Adhesion Assay—Cell adhesion assay was performed as de-
scribed previously (21). Briefly, 96-well microtiter plates (Nunc, Wies-
baden, Germany) were incubated with different types of laminins or
fibronectin at 37 °C for 1 h and then blocked with phosphate-buffered
saline containing 1% bovine serum albumin for another h at the same
temperature. A549 cells were trypsin treated and suspended in serum-
free DMEM at a density of 3 3 105 cells/ml; then 0.1 ml of the cell
suspension was added to each well of the plates followed by incubation
at 37 °C for 1 h. The attached cells were fixed and stained with a 0.4%
crystal violet in methanol (w/v) for 30 min. After washing with distilled
water, the stained cells were extracted with 0.1 M citrate in 50% etha-
nol. The absorbance of each well of the plates was measured at 590 nm
with a model 3550 microplate reader (Bio-Rad). Photomicrographs of
cells stained with Diff-Quik (International Reagents Corp., Kobe, Ja-
pan) were taken on Minicopy films (Fuji Photo Film Co., Ltd., Tokyo)
with an Olympus IMT-2 microscope (Olympus Optical Co., Ltd., Tokyo).
To identify the receptor for laminin-10/11, monoclonal antibodies
against different types of integrins were preincubated individually with
A549 cells in a volume of 0.05 ml of incubation solution (4 3 105
cells/ml) at room temperature for 15 min. The preincubated cells were
transferred onto plates precoated with different proteins and then in-
cubated further at 37 °C for 30 min. After staining with crystal violet,
the attached cells were quantified as described above.
Determination of Protein Concentration—Protein concentration was
determined by the dye method using a Bio-Rad protein assay kit.
RESULTS
Screening of Human Tumor Cell Lines for Expression of
Laminin a5 Chain—To purify and characterize human lami-
nin-10/11, we screened by RT-PCR a panel of 31 human tumor
cell lines for expression of the laminin a5 chain. The PCR
primers were designed according to the nucleotide sequence of
human a5 chain cDNA encoding the IIIb domain, which had
been cloned by RT-PCR from total RNA extracted from human
cervix epidermoid carcinoma cells using primers modeled after
the mouse a5 cDNA sequence (5). Expression of the laminin a1
chain, the a chain of the classical laminin-1, was also screened
by RT-PCR in parallel to select cells expressing a5 but not a1.
One of the human lung adenocarcinoma cell lines, A549, was
found to express the a5 chain mRNA at relatively high levels
but not that of a1 chain, although another lung carcinoma cell
line, RERF-LC-AI, expressed a1 but not a5 (Fig. 1A).
To confirm the selective expression of the a5 chain by A549
cells, the conditioned medium of A549 cells was analyzed for






















expression of a5 and a1 chains by immunoblotting with mono-
clonal antibodies specific to each laminin a chain. The mono-
clonal antibodies were produced by immunizing mice with re-
combinant GST fusion proteins containing the IIIb domain of
either the a5 or a1 chain. Immunoblotting with the monoclonal
antibody against the a5 chain (clone 15H5) specifically detected
a protein band migrating at the ;800-kDa region in the con-
ditioned medium of A549 cells but not that of RERF-LC-AI cells
(Fig. 1B). In contrast, the monoclonal antibody against the a1
chain (clone 5A3) specifically stained a protein band migrating
at the same region in the conditioned medium of RERF-LC-AI
cells, but not that of A549 cells. The ;800-kDa protein secreted
by A549 cells was strongly reactive with a monoclonal antibody
specific to the laminin g1 chain and migrated only slightly
above the a1-containing laminin variant(s) secreted by RERF-
LC-AI cells. Immunoblotting with antibodies specific for the a2
or a3 showed that no detectable amounts of these laminin a
chains were expressed by A549 cells (data not shown). Because
the anti-g1 chain antibody did not detect any bands corre-
sponding to the molecular masses of the a4 chain-containing
laminin-8 or laminin-9 (i.e. 500–600 kDa) in the conditioned
medium of A549 cells, it is likely that A549 cells express only
laminin-10 (a5b1g1) or laminin-11 (a5b2g1) among the 11
laminin variants identified to date. Because laminin-10 and
laminin-11 differ in their b chain types, we examined the
expression of laminin b1 and b2 chains in A549 and RERF-
LC-AI cells by RT-PCR (Fig. 1C). The results showed that both
b1 and b2 chains were expressed in both cell types, indicating
that A549 cells expressed both laminin-10 and laminin-11. The
relative amounts of the PCR products for b1 and b2 chains also
indicated that A549 cells expressed more b1 chain than b2
chain, whereas RERF-LC-AI cells expressed more b2 than b1.
These results suggest that laminin-10 is the major laminin
variant expressed in A549 cells.
Purification of Laminin-10/11—Laminin-10/11 in the condi-
tioned medium of A549 cells was purified by fractionation with
40% ammonium sulfate followed by immunoaffinity chroma-
tography using the monoclonal antibody 4C7, which was pre-
viously considered to recognize the a1 chain but has recently
been shown to recognize the a5 chain (19). The protein eluted
from a 4C7-Sepharose column gave a single band with molec-
ular mass of ;800 kDa on SDS-PAGE under nonreducing
conditions and three bands with molecular masses of 350, 220,
and 210 kDa under reducing conditions (Fig. 2A). The nonre-
duced ;800-kDa band was recognized by the anti-a5 mono-
clonal antibody 15H5 and also by monoclonal antibodies spe-
cific for the b1 or g1 (Fig. 2B), confirming that the purified
;800-kDa protein was either laminin-10 or a mixture of lami-
nin-10 and laminin-11. In support of this conclusion, the 350-
kDa and 210-kDa bands on the reducing gel were specifically
stained by monoclonal antibodies specific for the a5 chain (350-
FIG. 1. Expression of laminin-10/11 in human lung carcinoma
cells. Panel A, detection of transcripts encoding laminin a5 and a1
chains by RT-PCR. Transcripts encoding the IIIb domain of the a5 and
a1 chains were amplified by RT-PCR from two human lung carcinoma
cell lines, A549 and RERF-LC-AI, using the primer sets described under
“Experimental Procedures.” The expected sizes of the amplified cDNA
fragments corresponding to the a5 and a1 chains were 197 and 317 base
pairs, respectively. Panel B, detection of laminin (LN) a5, a1, and g1
chains by immunoblotting. The conditioned media of A549 and RERF-
LC-AI cell lines were subjected to SDS-PAGE on 4% polyacrylamide
gels under nonreducing conditions and transferred onto polyvinylidene
difluoride membranes followed by immunostaining with monoclonal
antibodies against human laminin a5 chain (15H5), a1 chain (5A3), or
g1 chain (2E8). The anti-g1 chain antibody was used as a panspecific
antibody detecting all of the known laminin variants except laminin-5
(a3b3g2). The position of the nonreduced EHS laminin-1 (;800 kDa) is
indicated in the left margin. Panel C, expression of laminin b1, b2, and
g1 chains in A549 and RERF-LC-AI cells. Transcripts encoding b1, b2,
and g1 chains were amplified by RT-PCR by using the primer sets
described under “Experimental Procedures.” The expected sizes of the
amplified cDNA fragments corresponding to the b1, b2, and g1 chains
were 248, 299, and 194 base pairs, respectively.
FIG. 2. SDS-PAGE and immunoblotting analyses of purified
laminin-10/11. Panel A, laminin-10/11 purified from conditioned me-
dium of A549 cells was subjected to SDS-PAGE using 4% polyacryl-
amide gels under nonreducing and reducing conditions. Proteins were
visualized by silver staining. Panel B, proteins separated by SDS-PAGE
under nonreducing (2ME2) and reducing (2ME1) conditions were
transferred onto polyvinylidene difluoride membranes followed by im-
munostaining with monoclonal antibodies specific for a5, b1, and g1
chains. Positions of EHS laminin-1 under reducing conditions (400 and
200 kDa) are indicated in the right margin.






















kDa band) and for the g1 chain (210-kDa band), respectively
(Fig. 2B). Weak reactivity of the anti-b1 monoclonal antibody
with reduced protein prevented identification of the subunit
type(s) of the 220-kDa chain (data not shown). However, the
apparent size of the chain was consistent with that of the b1 or
b2 chain, supporting the conclusion that the laminin variants
purified from the conditioned medium of A549 cells were a5
chain-containing laminin-10/11. The purified laminin-10/11 did
not show any detectable bands at ;150 kDa, indicating that
nidogen/entactin was not associated with the purified protein.
Cell Adhesion Activity and Receptor Binding Specificity of
Laminin-10/11—The cell adhesive activity of the purified
laminin-10/11 was compared with those of other laminin vari-
ants (i.e. laminin-1, laminin-2/4, and laminin-5) and fibronectin
using A549 cells. A549 cells readily attached and spread onto
surfaces coated with laminin-10/11, as was the case with sur-
faces coated with laminin-5 (Fig. 3). Cells spread on the lami-
nin-10/11-coated surface assumed an elongated, spindle-shape
morphology with thin processes, as opposed to the cells on the
laminin-5-coated surface which displayed a well spread cobble-
stone-like morphology with greater cell-substratum contact
area. Cells were less adherent to the surfaces coated with
laminin-1, laminin-2/4, or fibronectin with limited cell spread-
ing at the same coating concentration. In support of this con-
clusion, quantitative analysis of cells adhering to surfaces
coated with increasing concentrations of different adhesion
proteins showed that laminin-10/11 and laminin-5 were almost
equally active in mediating adhesion of A549 cells, exhibiting
maximal activity at concentrations as low as 3 nM. At this
concentration, other laminin variants as well as fibronectin
were barely capable of supporting cell adhesion (Fig. 4). The
coating concentrations for half-maximal adhesion were ;2 nM
for laminin-10/11 and laminin-5, 4 nM for laminin-2/4, 5 nM for
fibronectin, and 6 nM for laminin-1. Similar results were also
obtained with other cell types including A172 human glioma
cells and A431 human epidermoid carcinoma cells (data not
shown).
Because cell adhesion onto the laminin-coated substratum is
mediated predominantly by the integrin family of adhesion
receptors, we examined the effects of function-blocking mono-
clonal antibodies against various integrin subunits on adhesion
of A549 cells onto the surfaces coated with laminin-10/11 or
other adhesive proteins (Fig. 5). Adhesion onto surfaces coated
with laminin-1, laminin-5, and fibronectin was specifically in-
hibited by antibodies against integrin a6, a3, and a5 subunit,
respectively, and also by the antibody against integrin b1 sub-
unit, consistent with previous reports (12, 21, 22). Interest-
ingly, adhesion of A549 cells onto laminin-10/11-coated sur-
faces was inhibited completely by anti-integrin a3 antibody
and by anti-integrin b1 antibody, but not by antibodies against
other a subunits including anti-a6 antibody. These results
indicated that cell adhesion onto laminin-10/11 is mediated by
integrin a3b1, as is the case with laminin-5. Specific inhibition
of the laminin-10/11-mediated cell adhesion by anti-integrin a3
subunit antibody was also observed with A172 glioma cells
(data not shown).
DISCUSSION
The newest laminin a chain identified to date, a5, has been
established as the most widely expressed a chain in mamma-
lian tissues. The anti-human laminin monoclonal antibody
4C7, which was reported initially to be directed against the a1
chain, has been shown to recognize the a5 chain (19), resolving
the previous discrepancy in histological distribution between
mouse laminin-1 and its human counterpart defined by 4C7 (2).
Immunohistochemical studies using 4C7 and other antibodies
specific for mouse a5 chain showed that the a5 chain is local-
ized in basement membranes of a wide variety of epithelial
tissues and of blood vessels (4, 23, 24). Despite the ubiquitous
distribution of the a5 chain, however, the biological functions of
the laminin variants containing the a5 chain remain to be
determined, mainly because these laminin variants have not
been purified in intact form. This study was performed to
characterize the biological activities of laminin-10/11 using
purified, intact proteins.
The strategies employed to purify laminin-10/11 were as
follows. First, we selected a human cell line that expresses only
a5 chain by screening more than 30 different human tumor cell
lines by RT-PCR and immunoblotting. Conditioned medium of
cultured cells is superior to tissue extracts as a source of intact
FIG. 3. Attachment and spreading of A549 cells on surfaces
coated with laminin-10/11 and other adhesive proteins. A549
cells (2 3 104) were seeded onto 96-well microtiter plates coated with
laminin-10/11 (LN10/11), mouse laminin-1 (LN1), laminin-2/4 from
human placenta (LN2/4), laminin-5 (LN5), or fibronectin (FN) and
incubated for 60 min at 37 °C. The protein concentration used for
coating was 5 nM. The cells were rinsed with DMEM, fixed in methanol,
and stained with Diff-Quik. Bar, 50 mm.
FIG. 4. Adhesion of A549 cells onto surfaces coated with lami-
nin-10/11 and other adhesive proteins. 96-well microtiter plates
were coated with increasing concentrations of laminin-10/11 (LN10/11,
●), mouse laminin-1 (LN1, f), laminin-2/4 from human placenta
(LN2/4, ‚), laminin-5 (LN5, M), or fibronectin (FN, E) and incubated
with A549 cells at 37 °C for 1 h. After incubation, cells attached to the
surfaces were quantified by crystal violet staining as described under
“Experimental Procedures.” Each point represents the mean of tripli-
cate assays.






















laminins because the laminin variants reactive with the 4C7
antibody can be solubilized only after proteolytic digestion (e.g.
pepsin digestion) but not by neutral salt or EDTA extraction,
which instead solubilizes laminin-2/4 (25, 26). Second, we pro-
duced a monoclonal antibody that specifically recognizes hu-
man a5 chain on immunoblots. The availability of such a mono-
clonal antibody is crucial to identify the a5 chain because final
verification of purified laminin-10/11 requires immunoblotting
under reducing conditions. No such monoclonal antibodies rec-
ognizing reduced, denatured human a5 chain have been re-
ported to date. We also produced a monoclonal antibody that
specifically recognizes a1 chain on immunoblots. The a1 chain
has a molecular mass similar to that of a5 chain, and therefore
it is important to distinguish these two a chains with specific
antibodies. Previous confusion regarding the specificity of 4C7
antibody also made it crucial to distinguish a1 and a5 chains on
immunoblots. Third, we employed affinity chromatography
with 4C7-Sepharose to ensure the authenticity of the purified
protein. Based on these strategies, we selected A549 cells as a
source for human laminin-10/11 and purified them on a 4C7-
Sepharose column. In a separate experiment, we also purified
laminin-10/11 by conventional procedures for purification of
laminins from tissues, i.e. size fractionation on Sepharose 4B-
CL, heparin-Sepharose chromatography, and ion exchange
chromatography with HiTrap Q-Sepharose. The resulting lami-
nin-10/11 preparation contained some contaminant proteins
but exhibited essentially identical cell adhesive and integrin
binding activities as observed with those purified by 4C7 im-
munoaffinity chromatography.2
The laminin-10/11 thus purified gave a single band migrat-
ing at ;800 kDa under nonreducing conditions and consisted of
three chains of 350, 220, and 210 kDa. Based on the reactivity
with monoclonal antibodies specific for a5, b1, or g1 chain on
immunoblots, we concluded that the 350-kDa chain was a5 and
the 210-kDa chain was g1. Other a chains including a1, a2, and
a3 were not detectable in the purified laminin-10/11. The ab-
sence of a 500–600-kDa protein in the purified laminin-10/11
also made it unlikely that the a4 chain-containing laminin
variants copurified with laminin-10/11. Weak reactivity of the
anti-b1 monoclonal antibody with reduced, denatured protein
failed to identify the 220-kDa chain, but the 220-kDa chain is
considered to be a mixture of b1 and b2 chains because both
transcripts encoding b1 and b2 chains were detectable in A549
cells by RT-PCR. The presence of the b1 chain was verified by
positive staining of the unreduced ;800-kDa band with the
anti-b1 antibody.
The relative molecular mass of the a5 chain estimated from
SDS-PAGE (350 kDa) was significantly smaller than the mass
of mouse a5 chain (450 kDa) calculated from the amino acid
sequence predicted from the cDNA (5), raising the possibility
that the a5 chain expressed in A549 cells is processed post-
translationally proteolysis as observed with the a2 and a3
chains (27, 28). Consistent with our observation, the a5 chains
expressed in human choriocarcinoma cells (19) and in mouse
endothelial cells (24) were also found to be significantly smaller
than the predicted mass. It is also possible that the 350-kDa
form of a5 chain was generated by alternative RNA splicing, as
has been reported for the a3 chain (29).
Using purified laminin-10/11, we demonstrated that lami-
nin-10/11 is a highly adhesive protein, as potent as laminin-5 in
mediating cell attachment and spreading onto the substratum.
Cell adhesion onto laminin-10/11-coated surfaces was medi-
ated by integrin a3b1 but not by a6b1. Integrin a3b1, once
thought to be a promiscuous receptor recognizing laminin-1,
collagen, and fibronectin with low affinities, has been shown to
recognize laminin-5 preferentially (21, 22, 30–32). Our results
indicate that integrin a3b1 is a dominant surface receptor
recognizing both laminin-5 and laminin-10/11, both of which
are major constituents of basement membranes of a wide vari-
ety of epithelial tissues. Although our results provide the first
clear evidence demonstrating the integrin binding specificity of
laminin-10/11, there have been previous reports on identifica-
tion of integrin types binding to human laminin. Gehlsen et al.
(33) reported that integrin a3b1 was specifically bound by an
affinity column of human laminin which was prepared from
placenta after pepsin digestion followed by immunoaffinity
chromatography with a B1 (b1) chain-specific monoclonal an-
tibody (34). Although the laminin used in their study appeared
to be a mixture of truncated forms of laminin variants contain-
ing the b1 chain, its strong reactivity with 4C7 (25) indicated
that the human laminin from pepsinized placenta contained a
significant amount of laminin-10/11 in truncated form. In sup-
port of this, we found that human placental laminins obtained
from different commercial sources, either purified after pepsin
digestion or EDTA extraction, were strongly reactive with our
anti-a5 monoclonal antibody on immunoblots.2 The specific
binding of integrin a3b1 to an affinity column of human lami-
nin from pepsinized placenta is therefore consistent with our
conclusion that laminin-10/11 is specifically recognized by in-
tegrin a3b1. Essentially an identical approach was also taken
by Sonnenberg et al. (35) to identify laminin-binding integrin
types, resulting in a similar conclusion except that human
laminin could also bind to integrin a6b1 with lower affinity.
The apparent discrepancy between these two previous reports
may have been caused by the differences in the proportion of
laminin-10/11 relative to other contaminant laminin variants.
Among three other laminin variants examined in this study,
laminin-10/11 seems to be more related to laminin-5 than to
other laminin variants (i.e. laminin-1 and laminin-2/4) in ad-2 Y. Kikkawa, unpublished observation.
FIG. 5. Effects of anti-integrin monoclonal antibodies on adhe-
sion of A549 cells to plastic substrates coated with laminin-10/11
and other adhesive proteins. Wells of microtiter plates were coated
with 4 nM laminin-10/11 (LN10/11), 30 nM laminin-1 (LN1), 4 nM
laminin-5 (LN5), or 12 nM fibronectin (FN). A549 cells were preincu-
bated with the following function-blocking monoclonal antibodies
against integrin subunits at a 100 3 dilution for ascites or at a concen-
tration of 10 mg/ml IgG for 15 min at room temperature and were then
added to the precoated wells: a2, anti-integrin a2 subunit antibody
(P1E6); a3, anti-integrin a3 subunit antibody (P1B5); a5, anti-integrin
a5 subunit antibody (8F1); a6, anti-integrin a6 subunit antibody
(GoH3); b1, anti-integrin b1 subunit antibody (4G2). After a 30-min
incubation, cells attached to the substrates were quantified by crystal
violet staining as described under “Experimental Procedures.” The
numbers of adhering cells are expressed as percentages of the number
of cells adhering in the absence of monoclonal antibodies. Each column
represents the mean of triplicate assays. Bars, standard deviation.






















hesive properties. Laminin-5 has been reported to be most
potent in mediating adhesion of keratinocytes (32), endothelial
cells (36), and glioma cells (12) among various adhesive pro-
teins including laminin-1, laminin-2/4, fibronectin, and
vitronectin. Our results showed that laminin-10/11 has potency
comparable to that of laminin-5 in mediating cell adhesion to
the substratum. Furthermore, both laminin variants seem to
be specifically recognized by integrin a3b1, although laminin-5
can also be recognized by integrin a6b4 which plays an impor-
tant role in hemidesmosome assembly (37). Furthermore, the a
chains of laminin-10/11 and laminin-5, i.e. a5 and a3, seem to
be evolutionally the most related among five different laminin
a chains (38). A full sized laminin a3 chain, a3B, was identified
recently in mouse and human, showing the highest homology to
the a5 chain at the amino acid level (4, 38). Despite these
similarities, however, it should be noted that morphologies of
cells adhering onto surfaces coated with either laminin-10/11
or laminin-5 were significantly different. Cells on laminin-10/
11-coated surfaces assumed an elongated morphology with
multiple thin processes, and those adhering to laminin-5-
coated surfaces assumed a cobblestone-like morphology. This
clear distinction in adhering cell morphology suggests that the
signals transduced from substrate-adsorbed laminin-10/11 and
laminin-5 through integrin a3b1 are functionally different. The
differences in signaling events could be either quantitative, i.e.
simply the result of differences in the binding affinity of these
laminin variants with integrin a3b1, which in turn determines
the magnitude of cytoplasmic signals elicited by the ligand-
ligated integrin, or qualitative, i.e. the result of differences in
the involvement of coreceptors such as dystroglycan and inte-
grin a6b4, which also bind to substrate-bound laminin variants
(39, 40). Furthermore, integrin a3b1 has been shown to asso-
ciate with transmembrane-4 superfamily proteins (41, 42) and
EMMPRIN (43). These integrin-associated membrane proteins
could be involved in the regulation of signaling events mediated
by ligand-ligated integrin a3b1, leading to different cell mor-
phologies on substrata coated with different laminin variants.
In summary, we purified laminin-10/11 from the conditioned
medium of A549 cells and demonstrated that it is highly com-
petent in mediating cell adhesion to the substratum in an
integrin a3b1-dependent manner. Given that laminin-10/11
are the predominant laminin variants of most epithelial tissues
and that integrin a3b1 is the most abundant integrin receptor
expressed in epithelial cells of different tissue types, specific
interaction of integrin a3b1 with laminin-10/11 may play a
central role not only in the adhesion of epithelial cells to un-
derlying basement membranes but also in the regulation and
maintenance of the differentiated phenotypes of epithelial cells
in vivo.
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